French drug firm Sanofi ‘obliged’ to reveal results of clinical tests on Dengvaxia vaccine
Senator Nancy Binay on Friday said multinational drug firm Sanofi Pasteur was “morally and ethically” obliged to inform the public what severe diseases came out in their clinical tests on their Dengvaxia vaccine.
The French pharmaceutical firm is the world’s fifth largest drug firm in terms of prescription sales.
She said that Sanofi and the Department of Health (DoH) must launch a nationwide information drive to reach out to parents whose children have taken the vaccine.
“We don’t want the warning to the public come too little, too late. Obviously, there were shortfalls and gaps in the vaccine’s safety profile,” Binay said.
She urged the DoH to temporarily stop the immunization program and conduct an audit which regions or provinces have not completed, or completed, all three doses of the vaccine.
The public need to know the circumstances surrounding the vaccine, what symptoms should be monitored, precautions, indications, contra-indications, side effects and possible adverse effects, she said.
The senator asked the DoH to put in place monitoring and public health surveillance to avoid any medical disaster.
Sanofi, in a statement, said that Dengvaxia provided persistent protection against dengue fever to those who had prior infection.
“For those not previously infected by dengue virus, however, the analysis found that in the longer term, more cases of severe disease could occur following vaccination upon a subsequent dengue infection,” Sanofi said.